The Zhitong Finance App learned that on October 12, the official website of the Drug Evaluation Center (CDE) of the China Drug Administration showed that a new indication of AstraZeneca (AZN.US) rilizumab injection will be included in the priority review and is suitable for reducing proteinuria levels in adult patients with primary IgA nephropathy (IgAN). Raylezumab is a blockbuster grade product owned by AstraZeneca, with global sales of US$4.718 billion (YOY +20.23%) in 2025.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.